ImQuest and Arisyn partner to develop infectious disease and cancer drugs
Arisyn has recently announced its acquisition of a series of inhibitors with demonstrated preclinical efficacy against HIV, hepatitis C virus (HCV), HTLV-I, influenza virus, herpes viruses and cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.